Effects of the Sprint and T-Mobile Merger on Cell Tower Infrastructure

After extensive debate in the federal court, the merging of Sprint and T-Mobile has been approved. Within the telecom industry, this reduces key players to three large companies instead of four. Hugh Odom, President of Vertical Consultants, discussed with Marketscale host Daniel Litwin what this merger means for telecom infrastructure and consumers.

As Sprint and T-Mobile merge, the federal government is urging a fourth player in the industry to become a key player. Odom, along with other experts in the industry, believe the player will be Dish. However, Odom pointed out that Dish estimates it will take seven years to reach a competitive coverage rate of seventy percent. For consumers, this will likely mean less competitive carrier rates for several years.

Cell Tower companies may use the risk of this shift in the industry to seek lower rental rates from property owners leasing space to these companies. As a consultant, Odom explained that property owners should be aware of this issue, but that ultimately this change in the industry may be “one step back, a lot of steps forward because it opens up the market.”

Over the next few years, Odom expects the main focus of carriers to be on expanding 5G coverage. The current two main players in the industry, Verizon and AT&T, are already competing in this area, and Sprint and T-Mobile’s merged company will be competing as well. On this topic, Odom said, “5G will be fuel that drives the next explosion in the industry,” and outlined the challenges this will pose for property owners and municipalities.

For more on the merger, check out Business Casual

 

 

For the latest news, videos, and podcasts in the Software & Technology Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More